(Z)-Leukadherin-1 (ADH-503 free base; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival[1].
(Z)-Leukadherin-1 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively[1].
| Animal Model: | KPC mice [p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/flox][1] |
| Dosage: | 30, 60, or 120 mg/kg |
| Administration: | Oral gavage; 60 days |
| Result: | Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
|
| Animal Model: | Male rats[1] |
| Dosage: | 30, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral gavage twice a day; on days 1 and 5 |
| Result: | Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.
|
![Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- Structure](/CAS/20200401/GIF/2055362-72-4.gif)
